How to cure cancer? The quest to find a cure for cancer has advanced since the 19th century, yet major obstacles remain. Today, key challenges in cancer treatment include cancer heterogeneity, complex tumour microenvironments, asymptomatic cancer, metastatic cancer, and drug resistance in cancer treatment. There are also significant challenges in ensuring widespread accessibility to cancer treatment and developing effective cancer prevention strategies. Explore these critical areas in the quest to find a cure for cancer.
As of 2024, we do not have a single, definitive cure for all cancers. However, significant progress has been made in developing highly effective cancer treatments and potential cures for certain types of cancer, particularly when detected early.
The first known attempts to treat cancer date back to ancient times, with surgical removal of tumours practiced by the Egyptians and Greeks. However, modern efforts to cure cancer began in the late 19th century.
Key milestones include William Halsted’s development of the radical mastectomy in the 1880s, followed by radiotherapy in 1901, chemotherapy in the 1940s, bone marrow transplants in the 1950s, and targeted therapy in the early 2000s. More recently, immunotherapy and CAR-T cell therapy have provided significant advances, particularly for hard-to-treat cancers.
Finding a cure for cancer is immensely challenging due to the complex nature of the disease. Here are some key challenges in cancer treatment faced by oncologists and cancer researchers in their efforts to find a cure for cancer:
Click to read more:
As a physician, what do you think are the key challenges in cancer treatment and the quest to find a cure for cancer? Please share your thoughts in the comment section below.
Cancer Heterogeneity
Cancer is not a single disease but a collection of over 200 different types, each with unique genetic mutations, behaviours, and responses to cancer treatment. Even within a single tumour, there can be significant variability in how cancer cells behave, making it challenging to target all cells effectively. This heterogeneity suggests that a universal cure for cancer may be impossible, as treatments must be tailored to the specific genetic and molecular profiles of each individual’s cancer.
In 2024, CRISPR and gene editing are at the forefront of addressing cancer heterogeneity. CRISPR technology allows researchers to edit or deactivate specific mutations within cancer cells, creating personalised therapies that directly target the genetic mutations driving each tumour. By honing in on these unique mutations, CRISPR-based approaches aim to overcome the variability within and between tumours, offering a promising step towards more targeted and effective cancer treatments.
Are You an Oncologist or Haematologist?
What is your opinion on asymptomatic cancer, cancer heterogeneity, complex tumour microenvironments ? Join M3 today and share your opinion
Complex Tumour Microenvironment
The tumour microenvironment (TME) plays a crucial role in cancer progression and response to cancer treatments by providing a supportive setting for cancer cells, which includes nearby immune cells, blood vessels, fibroblasts, and other structures. The TME can foster an immunosuppressive environment, making it difficult for the immune system to target tumour cells. This characteristic is a significant barrier to effective cancer treatment, as it enables cancer cells to evade immune detection and resist therapies like immunotherapy.
In 2024, research into targeting the tumour microenvironment (TME) has gained traction, focusing on “reprogramming” this environment to support immune responses rather than protecting cancer cells. Techniques like immune checkpoint inhibitors are critical in this area, as they counteract the immunosuppressive signals within the TME, reactivating immune cells to target tumour cells more effectively. Nanotechnology is being used to deliver drugs directly into the TME, altering its structure to improve immune cell infiltration and therapeutic effectiveness.
Targeted therapies aim to neutralise immunosuppressive factors within the TME, such as tumour-associated macrophages and regulatory T-cells, which otherwise help tumours evade immune detection. These innovations are enhancing the success of immunotherapies like CAR-T cell therapy and immune checkpoint blockade, particularly for cancers with resistant TMEs.
Challenges with Early Detection and Asymptomatic Cancer
Many cancers are asymptomatic in their early stages, making early detection difficult. Without noticeable symptoms, these cancers can grow undetected until they reach advanced stages, often having spread (metastasised) to other parts of the body, where treatment becomes more complex and less effective. Early detection is crucial, as it greatly improves the chances of successful cancer treatment. However, for most cancers, achieving reliable early detection remains challenging.
Recent advancements, especially in liquid biopsy technology, hold promise for detecting cancer earlier and more accurately. Liquid biopsies can identify tumour DNA (ctDNA) fragments in the bloodstream, providing a non-invasive approach to screening. By identifying genetic mutations associated with certain cancers, liquid biopsies allow for continuous monitoring, which is especially beneficial in detecting recurrence or response to cancer treatment.
Despite this potential, liquid biopsies are still limited in detecting very small or early-stage tumours, as not all cancers shed enough ctDNA or specific biomarkers into the bloodstream. Furthermore, while mammography, colonoscopy, and low-dose CT scans remain essential tools, their limitations in sensitivity mean some cancers may still go undetected until they are in more advanced, less treatable stages.
Ongoing research aims to improve the sensitivity and accuracy of liquid biopsies and other detection methods to make early cancer detection more achievable across various cancer types, improving outcomes for asymptomatic patients.
Challenges with Metastatic Cancer
The metastatic nature of cancer—its ability to spread from the original tumour to other parts of the body—remains a major obstacle in cancer treatment. Metastasis occurs when cancer cells break away, travel through the bloodstream or lymphatic system, and establish new growths in different tissues or organs. This spread complicates treatment, as metastatic tumours often behave differently from the primary tumour, requiring distinct and often more complex cancer treatment approaches.
In 2024, immunotherapy and CAR-T cell therapy are advancing to tackle metastatic cancer. CAR-T therapy, which modifies a patient’s own immune cells to target cancer, has shown promise, particularly in blood cancers, and ongoing research is expanding its applications to solid tumours where metastasis is prevalent. CAR-T cells and other immune-based therapies are designed to recognise and destroy cancer cells throughout the body, aiming to improve control over metastatic spread.
However, metastatic cancer presents additional challenges, such as drug resistance and immune evasion. Cancer cells in advanced stages often adapt to withstand treatment, limiting the effectiveness of standard cancer therapies. Immunotherapies, especially checkpoint inhibitors, are also being used to counteract these adaptive mechanisms, enhancing immune surveillance even in metastatic cases. Yet, metastatic cancer remains one of the most pressing challenges in oncology due to these complexities, driving ongoing cancer research into multi-targeted and adaptive cancer treatment strategies.
Drug Resistance in Cancer Treatment
Cancer cells are highly adaptable, often evolving quickly to resist cancer treatments. Even when therapies like chemotherapy, targeted therapies, or immunotherapies are initially effective, cancer cells can mutate, altering their genetic makeup to evade these drugs. This adaptability allows cancer cells to survive and proliferate despite treatments designed to eliminate them, leading to treatment resistance, which in turn causes relapses or progression of the disease.
In 2024, artificial intelligence (AI) and big data are becoming vital tools in addressing cancer drug resistance. AI technology can analyse large datasets from patient outcomes, genomic profiles, and treatment responses, identifying patterns and predicting how cancer cells might develop resistance. This predictive capability enables oncologists to adjust cancer treatment plans proactively, combining or sequencing therapies to prevent resistance before it occurs.
Drug resistance remains a significant challenge, as many cancers develop resilience not only to individual treatments but also to combination therapies. This resistance is due to genetic mutations, alterations in cell signalling pathways, and protective changes within the tumour microenvironment. Overcoming this cancer drug resistance remains one of the most critical hurdles in cancer treatment, as it demands a multifaceted approach to disrupt the cancer cells’ ability to adapt and survive.
Cancer Treatment Accessibility and Equity
Even when effective cancer treatments are developed, high costs and the complexity of delivering personalised cancer therapies, such as gene therapies or CAR-T cell treatments, make it challenging to scale these innovations to all patients. Inequities in access to advanced cancer treatments remain a pressing global issue, particularly for low- and middle-income countries where healthcare resources are limited.
In 2024, initiatives like biosimilar development and microbiome research are emerging as potential solutions. Biosimilars, which are more affordable versions of biologic therapies, are being developed to make existing cancer treatments more accessible. Additionally, microbiome research aims to enhance the effectiveness of current therapies, such as immunotherapy, by leveraging the body’s own microbial composition. These advancements could improve outcomes without the need for costly new drugs, making advanced care more attainable.
Collaborations between pharmaceutical companies, governments, and international health organisations are essential for reducing the cost and expanding access to advanced cancer treatments. Global research networks are also actively working to address disparities, focusing on delivering innovative cancer treatments to underserved populations and improving survival rates across different regions and socioeconomic groups.
Cancer Prevention and Lifestyle Factors
A significant number of cancers are linked to lifestyle factors like smoking, diet, alcohol use, physical inactivity, and exposure to toxins. Smoking, responsible for around 30% of all cancer deaths, is especially impactful, leading to most lung cancer cases. Likewise, a diet high in processed foods and sedentary behaviour increase risks for cancers such as colorectal, breast, and pancreatic. Excessive UV exposure from sun or tanning beds also raises the likelihood of skin cancers, including melanoma.
Despite this knowledge, widespread behavioural change remains difficult. Societal habits, economic challenges, cultural norms, and limited access to preventive healthcare make it hard for individuals to adopt healthier lifestyles. Additionally, the addictive nature of tobacco and alcohol complicates prevention efforts at a societal level.
In 2024, numerous public health campaigns target lifestyle-related cancer risks, promoting behavioural changes to reduce incidence. These initiatives focus on raising awareness about routine screenings and preventive habits, encouraging healthier choices to lower cancer risks across communities.
What are your thoughts on the key challenges in cancer treatment as an oncologist? Please share your insights in the comment section below.
Did you find this article "How to Cure Cancer? Challenges in Cancer Treatment" interesting?
Join M3 today and share your opinion
You Might Be Interested in:
Oncology Focus: Take Part in Oncology Market Research Studies
Are you working as an oncologist? Join our oncology panel to help shape the future of oncology! Take part in oncology market research studies
A Meaningful Way to Earn Extra Income | M3 Referral Program
Dr Jordan Frey thinks healthcare market research and M3 referral programs for healthcare professionals are a meaningful way to earn extra income with paid referral programs
Are You an Oncologist or Haematologist?
What is your opinion on new technologies and advancements in chemotherapy, hormone therapy, immunotherapy, and targeted therapy? Join M3 today and share your opinion
latest posts
Psychological Resilience in Healthcare Teams: Strengthening Workforce Stability in Pressured Systems
Resilience in healthcare is essential to prevent burnout in healthcare staff and strengthen multidisciplinary healthcare teams, improving wellbeing, collaboration, and patient outcomes.
The Physician’s Toolkit of Tomorrow: Innovations Changing Medical Practice in 2026
Healthcare innovation, digital health innovation, and medical practice innovation now focus on scalable solutions that reduce workload and improve patient outcomes.
6 Smart Side Hustles for Doctors in 2026: Moving from Overtime to Market-Research Income
In 2026, healthcare market research and related opportunities, such as telehealth platforms, medical advisory roles, doctor consulting opportunities, and medico-legal consulting, offer new ways for doctors to monetise their expertise, complementing rather than competing with clinical practice.
Join Today
Panel Members